Want to see COCP full AI Analyst Report?
Top Page
Cocrystal Pharma
(NASDAQ:COCP)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.00
▼(-11.50% Downside)
Action:Reiterated
Date:09/30/26
The score is held down primarily by weak fundamentals (large ongoing losses, continued cash burn, and a thinner balance sheet). Technicals are modestly positive but not strong enough to outweigh financial risk, while corporate updates (study progress and added financing) provide some upside support. Valuation remains unattractive on earnings-based metrics due to negative profitability.
Positive Factors
Clinical progress in norovirus program
Completion of dosing advances CDI-988 from enrollment into the data-generation phase, creating a meaningful clinical milestone. Earlier human testing showed favorable safety and tolerability, while the current study evaluates prevention and treatment efficacy in a defined norovirus challenge model.
Negative Factors
Persistent operating cash burn
Cocrystal continues to consume substantial cash because operating activities do not yet generate funding. Although burn has improved from 2024, persistently negative free cash flow means clinical development depends on outside financing or other non-operating sources over the coming periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical progress in norovirus program
Completion of dosing advances CDI-988 from enrollment into the data-generation phase, creating a meaningful clinical milestone. Earlier human testing showed favorable safety and tolerability, while the current study evaluates prevention and treatment efficacy in a defined norovirus challenge model.
Read all positive factors
Cocrystal Pharma (COCP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$20.61M
Dividend YieldN/A
Average Volume (3M)46.47K
Price to Earnings (P/E)―
Beta (1Y)0.98
Revenue GrowthN/A
EPS Growth38.55%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.80
Shares Outstanding19,263,200
10 Day Avg. Volume38,975
30 Day Avg. Volume46,471
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.35
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue41.13
Enterprise Value/Gross Profit41.13
Enterprise Value/Ebitda-1.37
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.69
Revenue Forecast (FY)N/A
Cocrystal Pharma Business Overview & Revenue Model
Company Description
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications,...
How the Company Makes Money
Cocrystal Pharma is a development-stage biotech, so its ability to generate recurring product sales is typically limited unless it has an approved and commercialized drug. Its primary ways of making money are: (1) Collaboration and licensing reven...
Cocrystal Pharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 330.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 330.00K | -5.05M | -12.54M | -15.17M | -12.39M | -8.79M |
| EBITDA | -9.89M | -8.46M | -17.38M | -20.97M | -17.75M | -13.99M |
| Net Income | -9.94M | -8.83M | -17.50M | -17.98M | -38.84M | -14.19M |
Balance Sheet | ||||||
| Total Assets | 4.65M | 9.71M | 13.46M | 31.26M | 40.84M | 79.39M |
| Cash, Cash Equivalents and Short-Term Investments | 2.17M | 7.03M | 9.86M | 26.35M | 37.14M | 58.70M |
| Total Debt | 1.34M | 1.50M | 1.81M | 1.85M | 297.00K | 534.00K |
| Total Liabilities | 3.60M | 3.38M | 3.93M | 4.88M | 1.27M | 1.84M |
| Stockholders Equity | 1.04M | 6.33M | 9.52M | 26.38M | 39.57M | 77.55M |
Cash Flow | ||||||
| Free Cash Flow | -8.15M | -8.20M | -16.49M | -14.78M | -21.51M | -12.77M |
| Operating Cash Flow | -8.14M | -8.19M | -16.48M | -14.67M | -21.43M | -12.72M |
| Investing Cash Flow | -12.56K | -12.00K | -8.00K | -118.00K | -74.00K | -52.00K |
| Financing Cash Flow | 5.57M | 5.37M | 0.00 | 3.99M | -27.00K | 38.47M |
Cocrystal Pharma Technical Analysis
Negative
1.13
Price Trends
1.12
Negative
1.07
Positive
1.11
Negative
Market Momentum
-0.01
Positive
40.83
Neutral
3.70
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COCP, the sentiment is Negative. The current price of 1.13 is below the 20-day moving average (MA) of 1.14, above the 50-day MA of 1.12, and above the 200-day MA of 1.11, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 40.83 is Neutral, neither overbought nor oversold. The STOCH value of 3.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COCP.
Cocrystal Pharma Risk Analysis
Cocrystal Pharma disclosed 53 risk factors in its most recent earnings report. Cocrystal Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cocrystal Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $10.12M | -3.49 | -31.88% | ― | 10.41% | 42.44% | |
49 Neutral | $13.71M | -0.32 | -165.71% | ― | ― | 77.68% | |
47 Neutral | $20.61M | -1.34 | -207.47% | ― | ― | 38.55% | |
39 Underperform | $2.64M | -0.08 | -423.84% | ― | -8.47% | 25.62% | |
38 Underperform | $11.86M | -0.43 | -126.02% | ― | ― | 78.51% |
* Healthcare Sector Average
COCP
Cocrystal Pharma
1.07
0.01
0.94%
CLRB
Cellectar Biosciences
1.45
-3.44
-70.35%
IMRN
Immuron
1.08
-1.00
-48.08%
BRTX
BioRestorative Therapies
1.91
-30.09
-94.03%
BIVI
BioVie
1.39
-0.56
-28.72%
Cocrystal Pharma Corporate Events
Business Operations and StrategyProduct-Related Announcements
Cocrystal Pharma Completes Dosing in Norovirus Phase 1b Study
Positive
Sep 9, 2026
On September 9, 2026, Cocrystal Pharma announced it has dosed the last subject in its Phase 1b human norovirus challenge study evaluating its oral antiviral candidate CDI-988 for both prevention and treatment of norovirus infections. CDI-988, whic...
Executive/Board Changes
Cocrystal Pharma Adds Veteran Leader to Board of Directors
Positive
Aug 18, 2026
On August 12, 2026, Cocrystal Pharma, Inc. appointed veteran physician and executive Carol L. Brosgart to its Board of Directors, effective immediately. The company noted that her selection involved no special arrangements, family relationships, o...
Business Operations and StrategyExecutive/Board Changes
Cocrystal Pharma strengthens board with antiviral expert appointment
Positive
Aug 17, 2026
On August 17, 2026, Cocrystal Pharma announced that it had appointed Carol L. Brosgart, MD to its Board of Directors, effective August 12, 2026. The move adds decades of experience in antiviral therapy, epidemiology and biopharma governance to the...
Business Operations and StrategyPrivate Placements and Financing
OPKO Health Boosts Stake in Cocrystal Pharma Financing
Positive
Aug 3, 2026
On August 3, 2026, Cocrystal Pharma announced that longtime investor OPKO Health increased its stake through a $5 million private placement, buying 5,474,053 unregistered common shares at $0.9134 each with no attached warrants or derivatives. The ...
Executive/Board ChangesShareholder Meetings
Cocrystal Pharma Shareholders Approve Governance and Oversight Measures
Positive
Jul 17, 2026
On July 14, 2026, Cocrystal Pharma, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders voted on key governance and oversight matters. The meeting covered the election of board members, ratification of the independent auditor for...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.